Comparison the Effect of Sitagliptin and Inositol on the Fertility Treatment in Polycystic Ovarian Syndrome

Comparison of the effect of Sitagliptin and Inositol on the Oocyte and Embryo Quality in Poly Cystic Ovarian Syndrome (PCOS) Patients Undergoing Intra Cytoplasmic Sperm Injection (ICSI)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240128060827N1

Enrollment

Registered

2024-02-11

Start date

2024-04-02

Completion date

Unknown

Last updated

2024-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic Ovarian Syndrome. Polycystic ovarian syndrome

Interventions

Intervention 1: Intervention group: Patients in the Intervention Group Received Sitagliptin Tablets 50 mg Every 12 Hours Made by Abidi Company and Inofolic Powder Including 2000 mg Myoinositol and 20

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: People with Polycystic Ovarian Syndrome Age Between 18 and 40 Years People who are Known Case of Polycystic Ovarian Syndrome Based on Sonographic and Laboratory Findings Contained in the Case file People who are Candidates for Infertility Treatment and ICSI Based on Infertility Records

Exclusion criteria

Exclusion criteria: People with Uterine Abnormalities (such as Asherman's Syndrome, Fibroids, Polyps, and a Diagnosis of Adenomyosis) Contraindications for Inositol and Sitagliptin Treatment Cycles with Embryo Donation or Prenatal Genetic Screening Endometriosis and Infertility with Unknown Cause Severe Male Factor Infertility

Design outcomes

Primary

Measure	Time frame
Oocyte Quality. Timepoint: 8 Weeks Later Use of Medications. Method of measurement: Microscope.;Embryo Quality. Timepoint: 8 Weeks Later Use of Medications. Method of measurement: Microscope.	—

Secondary

Measure	Time frame
Body Mass Index. Timepoint: At the beginning of the study and 8 weeks later. Method of measurement: Dividing Weight by Height to the Power of 2.;Luteinizing hormone. Timepoint: At the beginning of the study and 8 weeks later. Method of measurement: ELISA test.;Follicle stimulating hormone. Timepoint: At the beginning of the study and 8 weeks later. Method of measurement: ELISA test.;Fasting Blood Sugar. Timepoint: At the beginning of the study and 8 weeks later. Method of measurement: ELISA test.;Testosterone. Timepoint: At the beginning of the study and 8 weeks later. Method of measurement: ELISA test.	—

Measure

Time frame

Body Mass Index. Timepoint: At the beginning of the study and 8 weeks later. Method of measurement: Dividing Weight by Height to the Power of 2.;Luteinizing hormone. Timepoint: At the beginning of the study and 8 weeks later. Method of measurement: ELISA test.;Follicle stimulating hormone. Timepoint: At the beginning of the study and 8 weeks later. Method of measurement: ELISA test.;Fasting Blood Sugar. Timepoint: At the beginning of the study and 8 weeks later. Method of measurement: ELISA test.;Testosterone. Timepoint: At the beginning of the study and 8 weeks later. Method of measurement: ELISA test.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFateme Foroozanfard

Kashan University of Medical Sciences

fatemehforoozanfard@yahoo.com+98 31 3457 4191

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026